Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension

Viatris

Status: Completed

Conditions: Glaucoma; Ocular Hypertension

Treatments: Drug: Latanoprost-timolol maleate fixed combination ophthalmic solution

Study type: Observational

Funder types: Industry

Identifiers

NCT01191008

A6641056

Details and patient eligibility

About

The objective of this Investigation is to evaluate the safety and efficacy of long-term treatment with Xalacom in medical practice. Also, occurrence of unknown and known adverse drug reactions (ADRs) in subjects treated with Xalacom will be monitored during the survey period, and whether an additional treatment outcome investigation and/or a post-marketing clinical study is required in the future will be determined.

Full description

All the patients whom an investigator prescribes the first Xalacom® should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Enrollment: 661 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients need to be administered Xalacom® in order to be enrolled in the surveillance.

Exclusion criteria

• Patients not administered Xalacom®.

Trial design

661 participants in 1 patient group

Latan-timolol maleate fixed comb ophthalmic solution

Treatment:

Drug: Latanoprost-timolol maleate fixed combination ophthalmic solution